Latham & Watkins Advises Castle Biosciences in its US$74 Million Public Offering of Common Stock

A capital markets team represented the life sciences company in the offering.

June 29, 2020

Castle Biosciences, Inc., has announced the pricing of its underwritten public offering of 2,000,000 shares of its common stock at a price to the public of US$37.00 per share. The gross proceeds to Castle Biosciences from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be US$74.0 million. In addition, Castle Biosciences has granted the underwriters a 30-day option to purchase up to an additional 300,000 shares of common stock at the offering price, less the underwriting discounts and commissions. 

Latham & Watkins LLP represents Castle Biosciences, Inc. in the public offering with a capital markets team led by partners Peter Handrinos and Wesley Holmes, with associates Anthony Gostanian and Kiara Vaughn. 
 

Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.